WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Harbour BioMed, a global biopharmaceutical company developing innovative therapeutics in the field of immuno-oncology and immunological diseases, today announced an initial strategic collaboration for the development and manufacturing of Harbour's leading HCAb antibody.

The collaboration with WuXi Biologics will support the supply of Harbour's products for clinical trials under Investigational New Drug (IND) applications in China and worldwide.

"In about a year's time, our scientists have moved our leading HCAb molecule into IND enabling stage. We are excited to collaborate with WuXi Biologics to accelerate further development of this molecule. This collaboration is aligned with our strategy to partner with industry leaders to bring forward innovative therapeutics that will help patients," said Dr. Jingsong Wang, CEO of Harbour BioMed.

"Harbour's trust in WuXi Biologics to develop this novel format of HCAb is a strong testament of WuXi Biologics as a global leader in technology," commented Dr. Chris Chen, CEO of WuXi Biologics, "We have enabled more than 20 complex molecules to the clinic including different bispecific formats, ADCs, fusion proteins and novel protein scaffolds. We aim to empower anyone and any company to discover, develop and manufacture biologics from concept to commercial manufacturing."